INNOVATOR AND BIOSIMILAR INFLIXIMAB: COMPARABILITY ASSESSMENT OF THE HOST CELL PROTEINS AND PROTEIN HIGHER ORDER STRUCTURE
Posters | 2016 | WatersInstrumentation
LC/TOF, LC/HRMS, LC/MS, LC/MS/MS, 2D-LC
IndustriesPharma & Biopharma
ManufacturerWaters
Key wordscdrs, hdx, biosimilar, chain, host, inflixmimab, displayed, heavy, inflectra, hos, fractional, proteins, light, randomly, innovator, conformation, infliximab, cell, processing, deuterium, uptake, visualization, glycan, minor, regions, identical, location, among, chosen, assessment, sample, methods, region, global, relatively, condition, batch, peptides, data, generate, difference, structure, measure, uplc, acquity, protein, class, results, order, compared
Similar PDF
IDENTIFICATION AND QUANTIFICATION OF HOST CELL PROTEIN IMPURITIES IN HIGH PURITY MONOCLONAL ANTIBODIES DOWN TO 1 PPM: AN INTER-LABORATORY STUDY
2016|Waters|Posters
IDENTIFICATION AND QUANTIFICATION OF HOST CELL PROTEIN IMPURITIES IN HIGH PURITY MONOCLONAL ANTIBODIES DOWN TO 1 PPM: AN INTER-LABORATORY STUDY Catalin Doneanu1, Scott J. Berger1, Malcolm Anderson2, Brad Williams3, Matt Lauber1, Asish Chakraborty1 and Weibin Chen1 1 Waters Corporation, Milford,…
Key words
hcps, hcpshcp, hcpmab, mabmse, mseims, imsiaifgatgr, iaifgatgrlchdmse, lchdmsemaeerqdalr, maeerqdalrmobility, mobilitylcmse, lcmsenist, nistreference, referenceremicade, remicadepeptide, peptidehdmse
Identifying Monoclonal Antibody Mutation Sites Using the Agilent 1290 Infinity II 2D-LC Solution with Q-TOF LC/MS
2017|Agilent Technologies|Applications
Identifying Monoclonal Antibody Mutation Sites Using the Agilent 1290 Infinity II 2D-LC Solution with Q-TOF LC/MS Application Note Biopharmaceuticals and Biosimilars Authors Abstract Koen Sandra, Gerd Vanhoenacker, In recent years, 2D-LC has been highly promising for the detailed characterization Mieke…
Key words
infliximab, infliximabbiosimilar, biosimilaroriginator, originatorrplc, rplcslslspgk, slslspgkslslspg, slslspgydywgqgttltvssastk, ydywgqgttltvssastkcandidate, candidatenyygstydywgqgttltvssastk, nyygstydywgqgttltvssastkbiosimilars, biosimilarspeptide, peptidedimensional, dimensionaldimension, dimensionmutations, mutationsheavy
ApplicAtion SolutionS for BiophArmAceuticAlS A Focus on Protein Therapeutics Introduction: Key Challenges in Biopharmaceutical Characterization .............................................................................................5 7 PROTEIN mass aNalysIs comprehensive and routine characterization of proteins and peptides by lc/mS and lc/mS e ...............................................................9 characterization of an igG1 monoclonal Antibody…
Key words
uplc, uplcpeptide, peptideprotein, proteinwaters, watersacquity, acquityglycan, glycanantibody, antibodymass, massglycans, glycanspeptides, peptidessystem, systemmapping, mappinganalysis, analysisintact, intactmonoclonal
Comprehensive Biosimilar Comparability Assessment via Intact and Subunit RP-MS and IEX-UV-MS Using the Xevo™ G3 QTof System
2022|Waters|Applications
Application Note Comprehensive Biosimilar Comparability Assessment via Intact and Subunit RP-MS and IEX-UV-MS Using the Xevo™ G3 QTof System Samantha Ippoliti, Owen Cornwell, Lisa Reid, Ying Qing Yu, Emma Harry, Mark Towers Waters Corporation Abstract With the increasing prevalence of…
Key words
subunit, subunitcomparability, comparabilityiex, iexbiosimilar, biosimilarintact, intactassessment, assessmentvia, viacomprehensive, comprehensiveusing, usingcarboxypeptidase, carboxypeptidasemab, mabterminal, terminallysine, lysinevariant, variantvariants